Crossmark

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

Crossref DOI link: https://doi.org/10.1007/s10557-016-6666-1

Published Online: 2016-05-30

Published Print: 2016-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rosenson, Robert S.

Jacobson, Terry A.

Preiss, David

Djedjos, C. Stephen

Dent, Ricardo

Bridges, Ian

Miller, Michael
Funding

Funding for this research was provided by:

Amgen Inc.
License Information

License valid from 2016-05-30